0001209191-14-001746.txt : 20140106
0001209191-14-001746.hdr.sgml : 20140106
20140106160120
ACCESSION NUMBER: 0001209191-14-001746
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140102
FILED AS OF DATE: 20140106
DATE AS OF CHANGE: 20140106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MAIN STREET
STREET 2: SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: 101 MAIN STREET
STREET 2: SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumeray Mark
CENTRAL INDEX KEY: 0001527134
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 14509782
MAIL ADDRESS:
STREET 1: 101 MAIN STREET
STREET 2: SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-01-02
0
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001527134
Sumeray Mark
C/O AEGERION PHARMACEUTICALS, INC.
101 MAIN STREET, SUITE 1850
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2014-01-02
4
M
0
1000
13.01
A
1000
D
Common Stock
2014-01-02
4
S
0
400
70.2175
D
600
D
Common Stock
2014-01-02
4
S
0
600
71.4117
D
0
D
Stock Option (right to buy)
13.01
2014-01-02
4
M
0
1000
0.00
D
2021-11-01
Common Stock
1000
119000
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.03 to $71.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
100,000 shares of common stock underlying this option vest over a 46-month period, with one-twenty-fourth of the shares vesting on the grant date of November 1, 2011 and the remainder of the shares vesting monthly thereafter in forty-six equal installments; 30,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Juxtapid by the U.S. Food and Drug Administration; 20,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Lojuxta by the European Medicines Agency; and 10,000 shares of common stock underlying this option vest monthly in equal installments over a four-year period commencing upon approval of Juxtapid for the treatment of pediatric patients.
By: /s/ Anne Marie Cook, attorney-in-fact
2014-01-06